Investors Who Lost Money with NASDAQ: VERU Shares Should Contact the Shareholders Foundation in Connection with the Lawsuit Against Veru Inc.
03/14/2023 - 08:10 AM
SAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Veru Inc. (NASDAQ:VERU).
Investors who purchased shares of Veru Inc. (NASDAQ: VERU) prior to May 11, 2022 and continue to hold any of those NASDAQ: VERU shares also have certain options. Those NASDAQ: VERU investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On December 6, 2022, a lawsuit was filed over alleged Securities Laws Violations by Veru Inc. The plaintiff alleges that the defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the data from the VERU-111 Phase 3 trial and the Company's interactions with the FDA, that Veru Inc. misled its shareholders to believe that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies, and that VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
Those who purchased Veru Inc. (NASDAQ: VERU) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc. mail@shareholdersfoundation.com
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
SOURCE: Shareholders Foundation, Inc.
View source version on accesswire.com:
https://www.accesswire.com/743605/Investors-Who-Lost-Money-with-NASDAQ-VERU-Shares-Should-Contact-the-Shareholders-Foundation-in-Connection-with-the-Lawsuit-Against-Veru-Inc
VERU Rankings
#5486 Ranked by Stock Gains
VERU Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Consumer Non-Durables, Household/Personal Care, Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Miami
About VERU
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
